<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430507</url>
  </required_header>
  <id_info>
    <org_study_id>GRC 4039-203</org_study_id>
    <secondary_id>2011-000107-40</secondary_id>
    <nct_id>NCT01430507</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>TERRA</acronym>
  <official_title>A Phase IIb, 12 Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of Revamilast in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals Ltd. India</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glenmark Pharmaceuticals S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Glenmark Pharmaceuticals Ltd. India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) is a systemic autoimmune and chronic inflammatory disease that
      causes progressive damage to joints of the body, affecting the functional capacity. Effective
      management of patients with RA requires a multidisciplinary approach. Despite the various
      combinations, there is a significant population of RA patients who are not responding to
      these combinations or showing inadequate response to methotrexate alone. Hence, there is a
      need for a unique combination of drugs targeting different pathological process to yield the
      best results in those patients where prognosis is poor. Combination of revamilast with first
      line therapy like methotrexate could provide better treatment options to a larger population
      of RA patients having moderate to severe disease and who are inadequately controlled on one
      or the other DMARDs.

      This is randomized, double-blind, placebo-controlled, parallel group study. The study will
      include patients with active RA receiving stable and maximum tolerated dose of MTX.

      Patients will be recruited after providing written informed consent. After screening and run
      in period (single blind placebo for 4 weeks), patients will be randomized (meeting
      randomization criteria) in 1:2:2:2 ratios to receive either one of three doses (Low, Medium
      and High) of revamilast or placebo along with MTX.

      The primary objective of the study is to determine the percentage of patients achieving ACR20
      response at 12 weeks. Secondary objectives include determining percentage of patients with
      ACR50 and ACR70 response, change in DAS-28 score, change in serum CRP and ESR values and
      frequency and use of rescue medication.

      During the treatment period, there will be 5 further study visits at week 2, week 4, week 8,
      week 12, for efficacy, safety and tolerability assessment and visit at week 14 will be follow
      up visit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients achieving ACR20 response</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving ACR50 and ACR 70 response</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS-28 score</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum CRP and ESR values</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and use of rescue medication</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">406</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium Dose Revamilast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose Revamilast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo in Triple Dummy Format</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Revamilast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revamilast</intervention_name>
    <description>Tablet, Low dose, Once daily for 12 weeks</description>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revamilast</intervention_name>
    <description>Tablet, Medium dose, Once daily for 12 weeks</description>
    <arm_group_label>Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revamilast</intervention_name>
    <description>Tablet, High dose, Once daily for 12 weeks</description>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥18 to ≤ 65 years of age

          2. Documented history of RA; diagnosed according to the revised American College of
             Rheumatology criteria (ACR)

          3. Active RA defined as patients with:

               -  6 swollen joint counts

               -  6 tender/painful joint counts, and

                    -  At least two of the three following criteria:

                         -  Rheumatoid Factor positive or Anti CCP positive

                         -  CRP ≥1.2 times upper limit of normal reference range or ESR &gt;28 mm/hr

                         -  Morning stiffness lasting &gt;45 min for at least last4 weeks

          4. DAS-28 CRP values ≥ 4.5 at screening (visit 1)

          5. Patients must have been on stable (15 mg to 25 mg) or maximum tolerated dose of MTX
             for at least 12 weeks prior to screening

          6. The patient's written informed consent to participate in the study

          7. Female participants must have a negative serum pregnancy test at screening visit.

          8. Males must agree to use barrier while on study medication and for 90 days after taking
             the last dose of study medication

          9. Must meet the following laboratory criteria:

               -  Hemoglobin ≥ 9 g/dL

               -  White blood cell (WBC) count; ≥3.0 X 109/L

               -  Platelet count ≥ 100,000 /L (100 X 109/L)

               -  Serum creatinine &lt;1.5 mg/dL (or 133mol/L)

               -  Total bilirubin &lt;2.0 mg/dL

               -  AST &amp; ALT&lt;1.5 times upper limit of normal

        Exclusion Criteria:

          1. Diagnosis of RA prior to 16 years of age (Juvenile RA)

          2. Non-degenerative joint diseases or other joint diseases that could interfere with the
             evaluation of RA

          3. Patients with any other autoimmune rheumatic disorders with the exception of Sjogren's
             syndrome.

          4. Patients with first degree relative with immune deficiency

          5. History of infection with human immunodeficiency virus and/or active hepatitis B or C

          6. Severe disabling arthritis leaving the patient eligible for surgical intervention, or
             incapacitated and prostrated patients

          7. Patients with a history of drug or alcohol abuse or chronic smoking

          8. Uncontrolled diabetes mellitus

          9. Concurrent diseases that might interfere with the conduct of the study,

         10. ECG abnormalities judged by the investigator to be clinically significant

         11. History of using any other test drug, one month before the beginning of this trial

         12. Women who are pregnant or breast-feeding or on hormonal therapy

         13. Patients who in the Investigator's opinion might not be suitable for the study.

         14. Patients with a life expectancy of less than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Lalit Lakhwani</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharamceuticals SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advance Rheumatology Clinic</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahavir Hospital and Research Center</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sri Deepti Rheumatology Center</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krishna Institute of Medical Sciences</name>
      <address>
        <city>Secunderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Knee &amp; Hip Surgery</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat.</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rathi Orthopaedic &amp; Research Center</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shalby Hospitals</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chanre Rheumatology and Immunology centre and Research</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M S Ramaiah Medical College and Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennisha Rheumatology Care &amp; Diagnostics</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sushrut Hospital Research Centre and PG Institute of Orthopaedics</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vidarbha Arthritis &amp; Superspeciality Clinic</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chennai Meenakshi Multispeciality Hospital Limited</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chhatrapati Shahuji Maharaj Medical University</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjay Gandhi Postgraduate Institute of Medical Sciences</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Post Graduate Medical Education &amp; Research (IPGMER)</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brokenshire Memorial Hospital</name>
      <address>
        <city>Davao City</city>
        <state>Davao</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Perpetual Help Dalta Medical Center</name>
      <address>
        <city>Las Pinas City</city>
        <state>Metro Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manila Doctors Hospital</name>
      <address>
        <city>Manila</city>
        <state>Metro Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Santo Tomas Hospital</name>
      <address>
        <city>Manila</city>
        <state>Metro Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <state>Metro Manila</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine and Rheumatology, Chong Hua Hospital</name>
      <address>
        <city>Cebu</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Davao Doctor's Hospital</name>
      <address>
        <city>Davao</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddział Kliniczny Reumatologii i Ukladowych Chorob Tkanki Lacznej</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Wojewodztwo kujawsko pomorskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Reumed</name>
      <address>
        <city>Lublin</city>
        <state>Wojewodztwo lubelskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osrodek Badan Klinicznych Prof. Dr hab. med.</name>
      <address>
        <city>Lublin</city>
        <state>Wojewodztwo lubelskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Medica Pro Familia Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <state>Wojewodztwo lubelskie</state>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne MEDENS S.C. Grupowa Praktyka Lekarska</name>
      <address>
        <city>Chelm Slaski</city>
        <state>Wojewodztwo slaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Praktyka Lekarska Joanna Badowska</name>
      <address>
        <city>Czestochowa</city>
        <state>Wojewodztwo slaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Zespol Specjalistycznej Opieki Zdrowotnej</name>
      <address>
        <city>Wroclaw</city>
        <state>Wojewodztwo slaskie</state>
        <zip>50-403</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teaching Hospital Karapitiya</name>
      <address>
        <city>Galle</city>
        <state>Colombo</state>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colombo South Teaching Hospital</name>
      <address>
        <city>Colombo</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital of Sri Lnka</name>
      <address>
        <city>Colombo</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nawaloka Hospitals PLC</name>
      <address>
        <city>Colombo</city>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Romford</city>
        <state>Essex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Leeds Teaching Hosptial NHS Trust, Chapel Allerton Hospital</name>
      <address>
        <city>Leeds</city>
        <state>Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Sri Lanka</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2011</study_first_submitted>
  <study_first_submitted_qc>September 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2011</study_first_posted>
  <last_update_submitted>December 27, 2012</last_update_submitted>
  <last_update_submitted_qc>December 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-inflammatory drugs, DMARD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

